OBJECTIVES: The objective of this study was to investigate survival of ovarian cancer patients with BRCA1 and BRCA2 mutations compared to those without mutations in a population-based sample of incident epithelial ovarian cancer cases. METHODS: Follow-up for vital status was performed on a population-based sample of 232 women with incident epithelial ovarian cancer recruited between December 13, 2000 and September 30, 2003 in the Tampa Bay area. Survival analysis using Cox regression was performed on (1) all 232 cases and (2) the 209 invasive epithelial ovarian cancer cases. Results of the two analyses were similar, thus data involving the 209 invasive epithelial cancer cases are presented, as this was judged to be more clinically relevant. RESULTS: In the multivariate analysis, BRCA status and stage were statistically significant, and were adjusted for in the survival analysis model. The Kaplan-Meier method estimated expected survival at 4 years of 83% of BRCA2 carriers compared to 37% of BRCA1 carriers and 12% of non-carriers. There was a statistically significant difference between BRCA2 carriers and non-carriers (p = 0.013). No statistically significant survival differences were seen for BRCA1 carriers when compared with either BRCA2 carriers or non-carriers. CONCLUSION: These data suggest that BRCA2 mutation carriers with ovarian cancer may have better survival than BRCA1 carriers and non-carriers. The etiology of this possible survival advantage is currently unknown. Larger studies are needed to confirm these results and to clarify their etiology and clinical significance.
OBJECTIVES: The objective of this study was to investigate survival of ovarian cancerpatients with BRCA1 and BRCA2 mutations compared to those without mutations in a population-based sample of incident epithelial ovarian cancer cases. METHODS: Follow-up for vital status was performed on a population-based sample of 232 women with incident epithelial ovarian cancer recruited between December 13, 2000 and September 30, 2003 in the Tampa Bay area. Survival analysis using Cox regression was performed on (1) all 232 cases and (2) the 209 invasive epithelial ovarian cancer cases. Results of the two analyses were similar, thus data involving the 209 invasive epithelial cancer cases are presented, as this was judged to be more clinically relevant. RESULTS: In the multivariate analysis, BRCA status and stage were statistically significant, and were adjusted for in the survival analysis model. The Kaplan-Meier method estimated expected survival at 4 years of 83% of BRCA2 carriers compared to 37% of BRCA1 carriers and 12% of non-carriers. There was a statistically significant difference between BRCA2 carriers and non-carriers (p = 0.013). No statistically significant survival differences were seen for BRCA1 carriers when compared with either BRCA2 carriers or non-carriers. CONCLUSION: These data suggest that BRCA2 mutation carriers with ovarian cancer may have better survival than BRCA1 carriers and non-carriers. The etiology of this possible survival advantage is currently unknown. Larger studies are needed to confirm these results and to clarify their etiology and clinical significance.
Authors: Y Ben David; A Chetrit; G Hirsh-Yechezkel; E Friedman; B D Beck; U Beller; G Ben-Baruch; A Fishman; H Levavi; F Lubin; J Menczer; B Piura; J P Struewing; B Modan Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: Thomas S Frank; Amie M Deffenbaugh; Julia E Reid; Mark Hulick; Brian E Ward; Beth Lingenfelter; Kathi L Gumpper; Thomas Scholl; Sean V Tavtigian; Dmitry R Pruss; Gregory C Critchfield Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Haijuan Yang; Philip D Jeffrey; Julie Miller; Elspeth Kinnucan; Yutong Sun; Nicolas H Thoma; Ning Zheng; Phang-Lang Chen; Wen-Hwa Lee; Nikola P Pavletich Journal: Science Date: 2002-09-13 Impact factor: 47.728
Authors: Janusz Menkiszak; Jacek Gronwald; Bohdan Górski; Anna Jakubowska; Tomasz Huzarski; Tomasz Byrski; Małgorzata Foszczyńska-Kłoda; Olga Haus; Hanna Janiszewska; Magdalena Perkowska; Izabela Brozek; Ewa Grzybowska; Helena Zientek; Stanisław Góźdź; Beata Kozak-Klonowska; Krzysztof Urbański; Roman Miturski; Jerzy Kowalczyk; Anna Pluzańska; Stanisław Niepsuj; Jan Koc; Marek Szwiec; Kazimierz Drosik; Andrzej Mackiewicz; Katarzyna Lamperska; Elwira Strózyk; Dariusz Godlewski; Małgorzata Stawicka; Bernard Waśko; Marek Bebenek; Andrzej Rozmiarek; Izabella Rzepka-Górska; Steven A Narod; Jan Lubiński Journal: Int J Cancer Date: 2003-10-10 Impact factor: 7.396
Authors: S Malander; M Ridderheim; A Måsbäck; N Loman; U Kristoffersson; H Olsson; M Nilbert; A Borg Journal: Eur J Cancer Date: 2004-02 Impact factor: 9.162
Authors: Joyce Liu; Mihaela C Cristea; Paul Frankel; Susan L Neuhausen; Linda Steele; Verena Engelstaedter; Ursula Matulonis; Sharon Sand; Nadine Tung; Judy E Garber; Jeffrey N Weitzel Journal: Cancer Genet Date: 2012 Jan-Feb
Authors: Larissa A Meyer; Meaghan E Anderson; Robin A Lacour; Anuj Suri; Molly S Daniels; Diana L Urbauer; Graciela M Nogueras-Gonzalez; Kathleen M Schmeler; David M Gershenson; Karen H Lu Journal: Obstet Gynecol Date: 2010-05 Impact factor: 7.661
Authors: John R McLaughlin; Barry Rosen; Joel Moody; Tuya Pal; Isabel Fan; Patricia A Shaw; Harvey A Risch; Thomas A Sellers; Ping Sun; Steven A Narod Journal: J Natl Cancer Inst Date: 2012-12-20 Impact factor: 13.506
Authors: Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin Journal: Mol Oncol Date: 2009-02-21 Impact factor: 6.603